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Abstract
Introduction: The aim of this study was to assess the safety and efficacy of combined autologous bone marrow mononuclear cell and 
VEGF165 gene therapy in patients with diabetes mellitus suffering from critical limb ischaemia (CLI).
Material and methods: The administration of mononuclear cells (MNCs) and naked VEGF165 plasmid was performed in 16 limbs of 
16 patients with rest pain and ischaemic ulcers due to diabetes. MNCs and plasmid were injected into the muscles of the ischaemic limbs. 
The levels of VEGF in serum and the ankle-brachial index (ABI) were measured before and after treatment. The Visual Analogue Scale 
(VAS) was used to evaluate pain sensation. CT angiography was performed before and after three months of therapy. 
Results: Mean (± SD) plasma levels of VEGF increased non-significantly from 257 ± 80 pg/L to 391 ± 82 pg/L (p > 0.05) two weeks after 
therapy. The ABI improved significantly from 0.26 ± 0.22 to 0.49 ± 0.30 (p < 0.001) three months after therapy. A decrease in rest pain was 
observed in all patients; mean VAS decreased from 6.3 ± 1.4 to 1.2 ± 1.1 after three months (p < 0.002). Angiograms showed the develop-
ment of collateral vessels in 12 limbs. Ischaemic ulcers healed in 12 limbs. Amputation was performed in four patients only, because of 
advanced wound infection. However, the level of amputations was lowered below knee level in these cases. Complications were limited 
to transient leg oedema in two patients and fever in two patients.
Conclusions: Intramuscular bone marrow MNCs autotransplantation combined with the administration of phVEGF165 gene is safe, 
feasible and effective for patients with diabetes and CLI. (Endokrynol Pol 2013; 64 (2): 129–138)
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Streszczenie
Wstęp: Celem pracy była ocena bezpieczeństwa i skuteczności skojarzonej terapii autogennymi jednojądrzastymi komórkami szpiku kost-
nego oraz terapii genowej plazmidem VEGF165 u chorych z krytycznym niedokrwieniem kończyn dolnych spowodowanym cukrzycą.
Materiał i metody: U 16 chorych z bólami spoczynkowymi oraz niedokrwiennym owrzodzeniem kończyny dolnej w przebiegu cukrzycy 
zdecydowano o podaniu komórek jednojądrzastych i plazmidu VEGF165. Komórki jednojądrzaste szpiku oraz plazmid były podawane 
drogą iniekcji domięśniowych do mięśni niedokrwionej kończyny. Do oceny wyniku zastosowanej terapii określano poziom VEGF 
w surowicy oraz wskaźnik kostka-ramię. Do określenia stopnia odczuwania bólu została użyta skala wzrokowo-analogowa (VAS). Do 
wykazania w naczyniach wykonywano CT angiografię przed i po 3 miesiącach terapii.
Wyniki: Średnie (± SD) stężenie VEGF w osoczu wzrastało nieistotnie statystycznie z 257 ± 80 pg/l przed terapią do 391 ± 82 pg/l 
(P > 0,05) po 2 tygodniach od zakończenia leczenia. Wskaźnik kostka–ramię wzrósł istotnie statystycznie z poziomu 0,26 ± 0,22 
przed terapią do 0,49 ± 0,30 (p < 0,001) po 3 miesiącach terapii. Zmniejszenie bólu spoczynkowego obserwowano u wszystkich 
pacjentów, średnia wartość VAS zmniejszyła się z 6,3 ± 1,4 przed terapią do 1,2 ± 1,1 po 3 miesiącach (p < 0,002). Angiogramy 
wykazały rozwój naczyń krążenia obocznego w 12 kończynach. Niedokrwienne owrzodzenie zostało całkowicie wyleczone 
w przepadku 12 chorych. Amputacje przeprowadzono tylko u 4 pacjentów z powodu zaawansowanego zakażenia rany, jakkolwiek 
poziom amputacji obniżono w tych przypadkach poniżej kolana. Powikłania były ograniczone do przemijających obrzęków podudzi 
u 2 chorych i gorączki u 2 pacjentów.
Wniosek: Domięśniowa autotransplantacja komórek jednojądrzastych szpiku kostnego w połączeniu z podaniem phVEGF165 
genu jest bezpieczną oraz skuteczną metodą leczenia pacjentów z cukrzycą i krytycznym niedokrwieniem kończyn dolnych. 
(Endokrynol Pol 2013; 64 (2): 129–138)
Słowa kluczowe: stopa cukrzycowa, terapia genowa, VEGF, jednojądrzaste komórki szpiku kostnego
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Introduction
Diabetes mellitus (DM) is a common chronic disease 
with a significant morbidity and mortality rate. One 
devastating complication of diabetes is peripheral 
arterial disease (PAD) including critical limb ischaemia 
(CLI) — the most extreme form of diabetic angiopathy, 
which may result in limb loss. The prevalence of PAD 
in patients with the diabetic foot syndrome exceeds 
80% [1, 2].
At present, there is no available permanent cure 
for diabetic CLI [1–5]. Several investigations have 
indicated that in patients with diabetes, circulating 
endothelial progenitor cells (EPCs) exhibit impaired 
proliferation, adhesion, and incorporation into vascu-
lar structures. The adverse metabolic stress factors are 
associated with a reduced number and dysfunction 
of EPCs [6–8]. The severity of the disease necessitates 
amputation in more than a quarter of all patients 
[9–11]. Treatment goals for CLI include reducing the 
number of cardiovascular risk factors (i.e. quitting 
smoking). Local care is the second essential element 
of the treatment. In a large proportion of these pa-
tients, the anatomical extent and the distribution of 
PAD make the patients unsuitable for operative or 
percutaneous revascularisation [9, 12, 13]. Thus, the 
disease frequently follows an inexorable downhill 
course [1–4, 8, 9, 13]. Recent progress in molecular 
biology has led to the development of a new strategy 
to treat a variety of cardiovascular diseases [14–19]. 
The use of gene- based or cell-based therapy to induce 
therapeutic angiogenesis has opened up new possibili-
ties for CLI [20–23]. 
The transplantation of bone marrow- or blood-
derived EPCs has been shown to accelerate blood 
flow restoration, neovascularisation, and the healing 
of diabetic mouse skin [8–10]. Therefore, therapeutic 
angiogenesis induced by transplantation of functional 
EPCs into ischaemic tissues may represent a novel 
approach to diabetic patients with CLI. Based on our 
previous study and data from literature, we designed 
a human clinical trial of gene therapy using Vascular 
Endothelial Growth Factor (VEGF) gene and stem cells 
as an unblinded open-labelled pilot study [24–27].
The aim of this study was to assess the safety, feasi-
bility and clinical efficacy of intramuscular application 
of autologous bone marrow mononuclear cells (MNCs) 
with plasmid encoding human VEGF165 in diabetic 
patients with CLI. The idea was that the transfection 
along with the increase in GH levels would facilitate 
the sitting process of the marrow cells. Also, the results 
of this study will be used to estimate the development 
of angiogenesis caused by combined mononuclear cell 
and gene therapy.
CLI definitions
CLI is defined as 1) persistent, recurring rest pain 
requiring analgesia and an ankle systolic pressure of 
50 mm Hg and/or toe systolic pressure of 30 mm Hg, 
and/or 2) ulceration, gangrene, or non-healing wounds 
in the foot with ankle systolic pressure of 50 mm Hg, 
or toe systolic pressure of 30 mm Hg. The Fontaine 
classification stratified patients as class III (rest pain) or 
class IV (ulceration and/or gangrene) [10].
Material and methods
Cloning and preparation of plasmid DNA  
(phVEGF165)
For the treatment we used a eukaryotic expression 
vector encoding the VEGF165 gene [17, 18]. The prepa-
ration and purification of the plasmid from cultures 
of phVEGF165-transformed Escherichia coli were 
performed with the endotoxin-free column method 
(Qiagen Mega Kit, Qiagen Inc., Valencia, CA, USA). The 
purified plasmid was stored in vials and pooled for qual-
ity-control analysis. Aliquots of 2,000 µg of phVEGF165 
were diluted in sterile saline to the volume of 10 mL. 
10mL of a solution containing 2 mg of VEGF165 plasmid 
gene was added to a mononuclear cell concentrate and 
incubated for two hours before administration. 
Bone marrow collection and preparation
Bone marrow was harvested by 25–30 aspirations 
from iliac crests under general anaesthesia using 
a bone marrow collection set (Baxter): no less than 
four different well-spaced iliac crest puncture sites 
were carried out on each side. An average volume of 
500 mL of bone marrow was collected. ACD formula 
A was used to prevent clot formation. After collec-
tion, the marrow was filtered with 500 µm and 200 
µm filters included in the kit. MNCs were separated 
from the harvested marrow with an albumin-primed 
blood cell separator (Baxter Fenwall CS 3000 plus) 
according to the manufacturer ’s protocol. The final 
volume of the mononuclear cell concentrate was 
adjusted to 80 mL, and the final product was filtered 
with 50-µm-blood product filter (PALL). The CD34+ 
cell content was estimated by flow-cytometry accord-
ing to ISHAGE recommendations. The median final 
number of prepared MNCs was 1.58 × 109 (range 
from 0.77 × 109 to 3.83 × 109). The median number of 
collected CD34+ cells was 1.7 × 107 (range from 0.12 
× 107 to 4.25 × 107). Finally, we received 120 ml of 
mononuclear cell solution.
Patient cohort
Inclusion criteria: 1) type 2 DM; 2) CLI, including rest 
pain and non-healing ischaemic ulcers persisting for 
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at least 12 weeks; 3) resistance to conventional therapy 
of CLI for at least four weeks after hospitalisation; 4) 
ankle-brachial index (ABI) of less than 0.5 in the affected 
limb; 5) no possibility of surgical or percutaneous revas-
cularisation based on usual practice standards. 
Exclusion criteria: 1) severe retinopathy; 2) end-
stage renal disease; 3) heart failure and/or angina 
pectoris New York Heart Association (NYHA) clas-
sification III or IV; 4) liver dysfunction (grade B or C 
in the Child-Pugh classification); 5) malignancy or 
history of malignancy; 6) and/or inability to stand or 
walk without help. 
Patients were observed for four weeks under con-
ventional drug therapy to confirm that their clinical 
symptoms and objective parameters did not improve.
Subjects 
The study was performed on 16 patients presenting 
type 2 DM and CLI not eligible for open vascular or 
endovascular interventions, or who failed one or both 
of them. The patients were nine men and seven women 
aged from 48 to 78 years (mean age 60.83). The duration 
of diabetes ranged from 8.5 years to 21 years. All patients 
needed constant insulin administration every day with 
an average dose of 0.63 U/kg (range from 0.38 to 0.91 
U/kg per day). Three patients used both insulin and 
an oral hypoglycaemic drug (metformin) for optimal 
glucose control. The average haemoglobin A1c level was 
8.1% (range from 5.9–11.2%) All patients were evalu-
ated for DM and CLI; including rest pain, non-healing 
ulcer, and/or gangrene (Table I). The protocol of this 
study was approved by the Commission of Bioethics 
at the Wrocław Medical University (Approval no. KB-
926/2003) and written informed consents were obtained 
from all the patients before enrollment in the study.
Administration of therapy
The patients received conventional care for their ulcers. 
To remove extensive callus and necrotic tissue, wound 
debridement was performed. After wound dressing, 
pressure relief was provided. Broad-spectrum anti-
biotics were prescribed if ulcers showed clinical signs 
of infection. Adjustments to the treatment were per-
formed when indicated on the basis of microbiologic 
cultures and sensitivity testing. The patients received 
an intramuscular injection of MNCs and phVEGF165. 
After marrow aspiration and two hours of incubation 
with phVEGF 165, the concentrate was injected intra-
muscularly into the ischaemic lower limb below knee 
level. The injection sites to calf muscles were based on 
our previous study and data from literature [13, 24]. The 
volume of each injection was 1.5 mL (approximately 
80 injections to calf muscles — each 2 cm deep per 
session). The injections were given no later than three 
hours after bone marrow harvesting because our 
intention was to eliminate the possible loss of stem 
Table I. Clinical characteristics of patients
Tabela I. Charakterystyka kliniczna pacjentów
No. Sex Age Affected 
limb
Symptoms Localisation Hypertension Past smoking Previous history
1 F 68 Right Rest pain ulcer Toe No Yes Sympathectomy
2 M 59 Right Rest pain ulcer Heel No No Bypass (occluded)
3 M 46 Right Rest pain ulcer Toe and heel No Yes Sympathectomy
4 M 58 Left Rest pain ulcer Forefoot Yes Yes Bypass (occluded)
5 M 69 Left Rest pain ulcer Forefoot Yes Yes Bypass (occluded)
6 F 74 Right Rest pain ulcer Forefoot Yes Yes Sympathectomy
7 M 77 Left Rest pain gangrene Toe and heel Yes Yes Prostaglandin
8 M 64 Left Rest pain ulcer Toe No No Prostaglandin
9 F 48 Right Rest pain ulcer Toe Yes Yes Bypass (occluded)
10 M 71 Right Rest pain gangrene Forefoot No Yes Sympathectomy
11 F 61 Left Rest pain ulcer Toe and heel Yes Yes Bypass (occluded)
12 M 53 Left Rest pain gangrene Toe Yes Yes Prostaglandin
13 F 69 Left Rest pain ulcer Forefoot No No Prostaglandin
14 F 75 Right Rest pain ulcer Forefoot Yes No Prostaglandin
15 M 74 Left Rest pain ulcer Toe No No Prostaglandin
16 F 77 Right Rest pain ulcer Toe and heel No Yes Prostaglandin
CLI Yes No
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cells caused by extracorporeal storage of bone marrow 
cells, and to avoid prolonged exposure of plasmid to 
enzymatic degradation by nucleases from monocytes 
present in the mononuclear cell solution. In RT-PCR 
stem cell tests, similar levels of VEGF165 mRNA were 
detected before and after incubation with plasmid. 
These results prove a low rate of stem cell transfection 
by naked VEGF plasmid. However, based on our own 
data and data from the literature, we expected the oc-
currence of the transfection of connective tissue cells at 
the place of injection of VEGF plasmid [23, 24, 28]. The 
expected effect would be an increase in the production 
of VEGF by cells in ischaemic tissue, which would sig-
nificantly improve the settlement of the injected stem 
cells and their transformation into angioblasty cells.
Study protocol
Cardiac, haematological, infectious, renal, hepatic, 
metabolic, and clinical parameters were measured both 
before and after cell and gene application in order to 
monitor the effect of MNCs and phVEGF165, as well 
as possible side effects of the combined stem cell and 
VEGF165 plasmid therapy. During a 12-week follow-up 
period, all patients received a constant fixed dose of 
insulin on a daily basis. Heart rate, blood pressure, body 
temperature, haemoglobin, thrombocytes, leukocytes, 
C-reactive protein, plasma glucose level, creatinine, 
urea, uric acid, gamma GT, alkaline phosphatase, and 
alanine aminotransferase were measured at the begin-
ning and then one week, four weeks, and three months 
after the cells and gene transplantation. Before the 
administration of the gene, venous blood was drawn 
from the upper limb in order to evaluate VEGF165 
concentration. This material was then obtained seven, 
28 and 90 days following plasmid injection. Serum was 
centrifuged and frozen. VEGF165 concentration was 
then evaluated by means of the ELISA method using 
a kit from R&D Systems according to the manufac-
turer’s instructions. 
Resting ABI were calculated as the ratio of the low-
est pressure from either the posterior or anterior tibial 
artery divided by the highest brachial systolic pressure, 
which were obtained one week before and both one and 
three months after completing the injections of MNCs 
with phVEGF 165. 
Multislice helical computed tomography (MSHCT) 
performed using a GE Medical Systems LightSpeed 
16-slice device was used to evaluate the arterial supply 
of the lower limb in our patients. The first examination 
was carried out one week before the administration 
of stem cells and VEGF gene. The follow-up examina-
tion was performed three months after the initial test. 
CT angiography was performed after intravenous 
administration of 150 ml (ca 2 mL/kg b.w.) non-ionic 
low-osmolar monomer contrast medium (Iomeron 350 
mg I/mL) injected by a power-injector with a flow-rate 
set at 4 mL/sec. The scanning was initiated automati-
cally at the peak concentration of contrast medium in 
the distal part of abdominal aorta (about 25–30 seconds 
after the onset of contrast administration) and the ex-
amination included only the arterial phase. The field 
of view ranged from the aortic bifurcation down to 
the level of the feet. The following parameters were 
used in acquisition: 3.00 mm slice with overlapping 
sections of 2.0 mm, pitch of 0.9, tube voltage of 120 kVp, 
tube current of 170 mAs. Axial scans and basic sagittal 
and coronal reconstructions were initially reviewed 
and then additionally two- and three-dimensional 
reconstructions were performed. Each artery and 
collateral was analysed individually by two research-
ers in various reconstructions. We used: multiplanar 
reconstruction (MPR), curved planar reformation 
(CPR), and maximum intensity projection (MIP). MPR 
is the method that proved particularly useful in the 
assessment of thrombotic material, atherosclerotic 
plaques and CPR additionally in the case of tortuous 
collaterals. The MIP technique proved substantially 
useful after calcium-subtraction, but in order to avoid 
the potential reconstructing-related mistakes we also 
evaluated MIPs prior to calcium-subtraction. The 
calcium-subtraction and the ‘clipping tool’ functions 
significantly facilitated the evaluation of arterial ves-
sels localised close to bones, i.e. the popliteal artery 
between the femoral condyles. A radiologist who was 
unaware of the treatment status of the patients inter-
preted the CT angiograms. The evaluation was based 
on measurements of: 
 — the number of vessels;
 — the length of arterial vessels;
 — the width of the flow channel of each arterial vessel;
 — the presence of calcifications in walls and thrombotic 
material in the lumen of the vessels. 
The measurement of length was made twice for 
each vessel and the median length was calculated. 
We compared the results of both initial and follow-up 
examinations. An increase in either the number of ves-
sels, vessel length or vessel width was considered an 
improvement. 
Pain was evaluated using the Visual Analogue Scale 
(VAS) one week before treatment and 12 weeks after 
the administration of autologous bone marrow MNCs 
and VEGF plasmid.
Statistical analysis 
Paired chi square and Wilcoxon tests were used to 
compare continuous variables before and after therapy, 
and to evaluate the differences between the clusters of 
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measurements taken at individual time points. P < 0.05 
was considered significant.
Results
Clinical follow-up 
The series of intramuscular injections of MNCs with 
VEGF165 gene were well tolerated by most patients. 
Only two of them reported intense pain during the 
injections. No major complications were noted. Two 
patients reported lower limb tenderness at the injec-
tion sites for up to 24 hours following injections. Mild 
and transient limb oedema occurred in two patients. 
Fever was observed in two patients (Table II). However, 
neither leukocytosis increase and other reactions, nor 
any side effects, were observed in the patients in the 
course of our study. There were no significant changes 
in laboratory parameters during this study. No patient 
died or was hospitalised (for any other reason than 
follow-up) in the course of our 90-day observation 
period (Table III).
All patients were followed up for at least three 
months. Limb amputation due to advanced CLI with 
extensive foot ulceration or necrosis and severe wound 
infection was performed in four patients. All of them 
underwent below-knee amputation. The amputations 
were performed between the 10th and 12th week fol-
lowing MNCs and gene administration. In these four 
patients, the results were not satisfactory. In another 
12 patients, therapy caused rest pain recession and 
total healing of chronic foot ulcerations occurred up 
to 12 weeks after the administration of MNCs with 
VEGF gene. In the course of the healing process, we 
performed the surgical debridement of necrotic tissue. 
In these patients, the combined mononuclear cell/gene 
therapy was successful and their lower limbs were 
saved from amputation (Fig. 1–4).
Change in VEGF serum levels
During our 90-day observation period, fluctuations in 
cytokine VEGF levels occurred in the study subjects. 
Mean VEGF serum levels increased from 257 ± 80 
Table II. Safety analysis after administration of VEGF plasmid and stem cells
Tabela II. Analiza bezpieczeństwa terapii z użyciem plazmidu VEGF oraz komórek macierzystych
Clinical findings after administration of phVEGF/stem cells Number of patients (total = 16)
Deaths 0
Major complications: shock, peripheral embolisation, necrosis and pseudoaneurysm 0
Fever 2
Oedema 2
New cancer 0
Table III. Results of laboratory tests
Tabela III. Wyniki badań laboratoryjnych
Lab. parameters Before administration 
(mean ± SD)
Seven days after 
administration 
(mean ± SD)
28 days after 
administration 
(mean ± SD)
90 days after 
administration 
(mean ± SD)
Haemoglobin [g/dL] 13 ± 2.6 13 ± 1.4 12 ± 2.1 12 ± 1.5
Thrombocytes [× 1,000/μL] 242 ± 50 220 ± 25 238 ± 46 245 ± 31
Leukocytes [× 1,000/ μL] 8 ± 2 8 ± 3 9 ± 2 8 ± 2
C-reactive protein [mg/L] 12 ± 6 18 ± 6 13 ± 3 12 ± 3
Alanine aminotransferase [U/L] 25 ± 15 28 ± 16 26 ± 10 27 ± 13
Creatinine [μmol/L] 107 ± 20 99 ± 24 101 ± 25 102 ± 15
Figure 1. Patient No. 1 before treatment
Rycina 1. Pacjent nr 1 przed leczeniem
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pg/L to 391 ± 82 pg/L (P > 0.05) two weeks after the 
stem cell and gene therapy. It was the highest mean 
serum level recorded during this study. However, 
the changes of VEGF levels were highly variable. The 
observed levels did not significantly differ between 
patients with healed ulceration and those with an 
amputated limb (Table IV).
Plasma glucose levels
After 90 days of treatment, the mean fasting plasma 
glucose level significantly decreased from 8.00 ± 0.75 
mmol/L at baseline to 6.14 ± 0.67 mmol/L (p < 0.001) 
(Table V).
ABI results 
The mean ABI increased significantly from 0.26 ± 0.22 
to 0.42 ± 0.19 (p < 0.001) four weeks after the adminis-
Figure 3. Patient No. 2 before treatment
Rycina 3. Pacjent nr 2 przed leczeniem
Figure 4. Patient No. 2 after treatment
Rycina 4. Pacjent nr 2 po leczeniu
Table IV. Plasma level of VEGF
Tabela IV. Stężenie VEGF w osoczu
Time of 
measurement
Before administration 
(mean ± SD)
Seven days after 
administration 
(mean ± SD)
14 days after 
administration 
(mean ± SD)
28 days after 
administration 
(mean ± SD)
90 days after 
administration 
(mean ± SD)
Level of VEGF 257 ± 80 342 ± 85 391 ± 82 288 ± 78 259 ± 59
Figure 2. Patient No. 1 after treatment
Rycina 2. Pacjent nr 1 po leczeniu
Table V. Plasma glucose level
Tabela V. Stężenie glukozy w osoczu
Time of 
measurement
Before administration 
(mean ± SD)
Seven days after 
administration 
(mean ± SD)
28 days after administration 
(mean ± SD)
90 days after administration 
(mean ± SD)
Glucose (mmol/l) 8.00 ± 0.75  7.54 ± 0.83 6.49 ± 0.71 6.14 ± 0.67
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(after three months), the index increased significantly 
to 0.49 ± 0.30 (Table VI). The increase in the ABI was 
observed in 12 patients with completely healed ulcera-
tion. Unfortunately, four patients did not have a chance 
to complete the ABI examination due to amputation. 
CT angiography results
Generally, CT angiography documented the typical 
findings in advanced atherosclerotic changes in lower 
limb arteries in all 16 cases enrolled to this study. These 
findings included segmental occlusive disease involving 
primarily the distal superficial femoral artery and/or the 
popliteal artery (Fig. 5–7).
After the end of the therapy, the formation of new 
collateral vessels was observed in all cases without 
amputation (Fig. 8). The comparison of CT angiograms 
Figure 5. Patient No. 3 before treatment, CT angiography
Rycina 5. Pacjent nr 3 przed leczeniem, tomografia komputerowa 
z opcją naczyniową
Figure 6. Patient No. 3 before treatment, CT angiography
Rycina 6. Pacjent nr 3 przed leczeniem, tomografia komputerowa 
z opcją naczyniową
Figure 7. Patient No. 3 before treatment, CT angiography
Rycina 7. Pacjent nr 3 przed leczeniem, tomografia komputerowa 
z opcją naczyniową
Table VI. Ankle–brachial index results
Tabela VI. Ocena współczynnika kostka–ramię
Time of 
measurement 
One week 
before 
(mean ± SD)
One month after 
(mean ± SD)
Three months 
after 
(mean ± SD)
Ankle-brachial index 
(10 patients) 0.26 ± 0.22 0.42 ± 0.19 0.49 ± 0.30
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demonstrated an increase in the number (from initially 
two to four in the follow-up), length and width of 
collaterals arising from posterior tibial artery (PTA). 
Moreover, in 12 patients who saved their legs, in follow-
up angio-CTs, the lumen of PTA and tibio-fibular trunk 
appeared wider and more regular compared to the first 
examination (Fig. 9). The number of collaterals arising 
from the superficial femoral artery did not change, 
but CT angiograms showed qualitative evidence of 
improved distal flow after the stem cell and gene 
therapy (Fig. 10).
Rest pain (VAS)
Pain was measured using the VAS and decreased sig-
nificantly from 6.3 ± 1.4 before treatment to 1.2 ± 1.1 
after three months (p < 0.002). At the end of the study, 
decrease in pain severity was observed in 12 patients 
with completely healed ulceration. 
Discussion
The natural history of CLI has been well documented 
to have an inexorable downhill course [6–11]. There-
fore, amputation is often recommended as the solution 
of choice in these patients [12, 13]. This is the first study 
known to us describing the application of a combined 
Figure 8. Patient No. 3 after treatment, CT angiography
Rycina 8. Pacjent nr 3 po leczeniu, tomografia komputerowa 
z opcją naczyniową
Figure 9. Patient No. 3 after treatment, CT angiography
Rycina 9. Pacjent nr 3 po leczeniu, tomografia komputerowa 
z opcją naczyniową
Figure 10. Patient No. 3 after treatment, CT angiography
Rycina 10. Pacjent nr 3 po leczeniu, tomografia komputerowa 
z opcją naczyniową
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therapy using the simultaneous administration of 
MNCs and gene in patients with CLI due to diabetes. 
To the best of our knowledge, earlier trials described 
only treatment either with MNCs, or VEGF plasmid 
[21–23, 25, 27]. 
Our results are very promising. We achieved a sig-
nificant long-term (over 90 days) clinical improvement 
in patients with CLI initially qualifying for amputation. 
As a result of the treatment, in 12 out of 16 patients 
surgery proved unnecessary and limb salvage was 
achieved. We observed the healing of ulcerations in 
the ischaemic limbs and rest pain regression in these 
patients. Unfortunately, such spectacular effects were 
not observed in all patients following the combined 
mononuclear cell and gene treatment. In four patients 
with advanced CLI symptoms, amputations were 
necessary, but amputation levels were lowered below 
knee level, despite having been set above the knee 
before the combined therapy. This is also considered 
to be a positive effect of the treatment. In these cases, 
the need for amputation was due to severe ulceration 
of the lower limb. It seems that the combined mononu-
clear cell and gene therapy should be introduced much 
earlier in such cases. From the perspective of patients’ 
safety, no significant adverse effects were observed 
in any patients. Aside from some minor discomfort at 
the injection sites and peripheral oedema in two cases 
with fever in two cases, no other side effects were 
observed and – specifically – on long-term follow-up 
there was no evidence of any systemic effects of VEGF 
in terms of the development of retinopathy or new 
tumour growth.
The analysis of serum tests shows high initial 
VEGF165 concentration in the study subjects. It was 
statistically higher in all patients compared to healthy 
controls. The levels of VEGF also showed high vari-
ability from patient to patient. This situation seems to 
be due to much increased production of VEGF protein 
by the critical ischaemic muscles in the affected limb [28, 
29]. During our 90-day observation period, fluctuations 
in cytokine levels occurred in the study subjects. Our 
results of VEGF level in serum demonstrate a significant 
increase in VEGF up to four weeks after gene therapy. 
The prolonged high level of VEGF in our trials seems 
to be related to an increased production of cytokine 
by the transfected muscle cells at the injection sites, 
and we hope that we have successfully transfected 
the stem cells [13, 15, 18, 24, 28]. It seems to depend 
on the high production of VEGF by the transfected 
cells in the ischaemic tissues [29]. The analysis of the 
clinical outcomes obtained in these patients, as well 
as the haemodynamic and imaging data, should be 
cautiously interpreted as very promising. Our results 
also provided preliminary evidence of the potential 
efficiency of the mononuclear cell and gene therapy in 
the treatment of CLI due to diabetes. Especially, the ABI 
increased significantly in 12 patients with successfully 
healed ulcerations (p < 0.05). Improved blood supply 
was achieved due to an increase in the number, length 
and width of collaterals arising from PTA, widening 
of PTA and tibio-fibular trunk that also became more 
regular (despite persistent stenosis or occlusion of the 
superficial femoral artery and/or the popliteal artery). 
To the best of our knowledge, such an improvement 
of the ABI is difficult to achieve with pharmacological 
treatment in patients with CLI due to diabetes [30]. 
Unfortunately, at the same time no improvement was 
documented in the amputated limbs of four patients. It 
seems that in these cases the damage to microcirculation 
in the affected limbs was too advanced to be improved 
by angiogenesis induced by stem cells from MNCs and 
VEGF165 plasmid. CT angiography showed increased 
flow in calf arterial vessels in all cases with successfully 
healed ulcerations. Also angiograms showed the forma-
tion of new collateral vessels in all 12 surviving limbs. Im-
provement of rest pain was reported in 12 (75%) patients 
with successfully healed wounds in the lower limb. The 
failed results in four cases (25%) can probably be explained 
by advanced critical ischaemia symptoms with irreversible 
damage to microcirculation. In these cases, therapeutic 
angiogenesis was too weak a signal of the restoration of 
the peripheral vascular bed in critical ischaemic muscles. It 
seems that the mononuclear cell and gene therapy should 
be introduced earlier in such cases [30, 31]. 
Conclusions
Our study has several limitations: it was not ran-
domised, placebo-controlled, or double-blind. How-
ever, we evaluated the improvement in limb perfusion 
by reducing ischaemic pain, signs of wound healing, 
improved ABI and formation of new vessels after cell 
and gene transplantation. We found that the combined 
administration of intramuscular MNCs and VEGF gene 
was safe and effective in 75% of our patients with lower 
limb ischaemic necrosis due to DM. 
In summary, from our observations we conclude 
that our method is a very promising form of therapeutic 
angiogenesis.
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